Michael Mingzhao Xing

Molecular Biology · 2005

A researcher in the Science corpus: 1 paper; trusts 2 researchers and is trusted by 3 researchers here, as inferred from the citation graph.

Subfields

Whom Michael Mingzhao Xing trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. C. Peyssonnaux
  2. M. Nikiforova

Who trusts Michael Mingzhao Xing overall

  1. Mingzhao Xing
  2. Y. Nikiforov
  3. M. Nikiforova

Papers from Michael Mingzhao Xing's perspective

Ordered by how strongly the researchers Michael Mingzhao Xing trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status (Nature)
  2. Mutations of the BRAF gene in human cancer (Nature)
  3. The Raf/MEK/ERK pathway: new concepts of activation (Biology of the Cell)
  4. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. (Cancer Research)
  5. BRAF mutation in papillary thyroid carcinoma. (Journal of the National Cancer Institute)
  6. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. (Journal of the National Cancer Institute)
  7. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.
  8. Thyroid carcinoma. (The Journal of the National Comprehensive Cancer Network)
  9. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. (Journal of Clinical Oncology)
  10. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. (Journal of Clinical Endocrinology and Metabolism)

Their papers